QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: GVP Module VII — Multiple Products, Substances and Marketing Authorisation Holders

Test your understanding of the concepts covered by GVP Module VII: Multiple Products, Substances and Marketing Authorisation Holders.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What is the most appropriate treatment of a safety issue associated primarily with an injection technique in a PSUR covering oral and injectable formulations?

Exclude it because the active substance is common to both formulations Apply it equally to both formulations without qualification Present and evaluate it as a route- or formulation-specific issue while considering any broader relevance Prepare a separate PSUR automatically for the injectable product

Question 2 of 10 Which evidence chain best demonstrates traceability of a material PSUR conclusion?

Draft conclusion, author memory and final approval Product name, sales forecast and submission date Regulatory scope, included products and authorisations, source systems, extraction, analysis and conclusion Partner contract, marketing plan and safety committee minutes

Question 3 of 10 How should differences between product information in different jurisdictions generally be handled in the PSUR?

Assume that one global label automatically applies everywhere Ignore regional wording differences because the active substance is the same Distinguish common safety evidence from region-specific regulatory implementation Use the most restrictive wording as the mandatory wording for every market

Question 4 of 10 When may separate PSURs for different formulations or indications be appropriate?

Whenever separate business units find a common report inconvenient Only when the products have different brand names In exceptional circumstances, such as entirely different indications, subject to applicable regulatory requirements and competent-authority agreement where required Whenever one formulation has a lower exposure

Question 5 of 10 Separate internal teams reach materially different conclusions about the same active substance. What should governance do first?

Select the conclusion from the team with the largest database Average the conclusions to create a neutral position Reconcile differences in cutoff, population, indication, formulation, exposure, methods and scientific interpretation Discard the conclusion that identifies the greater risk

Question 6 of 10 Which situation presents a risk of double counting in a cumulative PSUR analysis?

A route-specific analysis is performed for an injectable formulation The same case is received through a spontaneous report and also provided by a partner Exposure is stratified by indication A historical regulatory action is reviewed in the worldwide status section

Question 7 of 10 Why can excluding a relevant formulation from a PSUR affect the benefit-risk conclusion?

It changes the legal name of the active substance It may result in incomplete exposure, missed cases and inaccurate risk characterisation It automatically invalidates every product authorisation It prevents the MAH from using any international data

Question 8 of 10 Different product names are used for medicinal products containing the same active substance. What should determine whether they fall within a common PSUR scope?

The number of commercial names The internal structure of the safety database Applicable regulatory requirements and the relevant authorisations Whether the products are promoted by the same commercial department

Question 9 of 10 What is the purpose of including a worldwide marketing authorisation perspective in the PSUR?

To replace the EU assessment with a global assessment To identify global authorisations, regulatory actions and safety information that may affect the overall and EU assessment To require identical product information in every jurisdiction To limit the report to centrally authorised products

Question 10 of 10 Three different MAHs market products containing the same active substance in different EU Member States. Where applicable, what is the role of PSUSA?

It treats the products as unrelated because their MAHs differ It allows related PSURs to contribute to a coordinated EU assessment of the active substance or combination It requires one MAH to assume ownership of all other MAHs' safety systems It replaces the need for each MAH to submit the documentation required for its product

QPPV.com

Knowledge Assessment: GVP Module VII — Multiple Products, Substances and Marketing Authorisation Holders

Cookie Settings